Table 1.
Clinical trials information.
| Study | Trial name | Country | Year | Total number of patients | Regimen | No. of patients | Medication weeks | Age | Sex(male/female) | Tumor location (U/M/L) | Tumor location (body/antrum) | Tumor depths (m/sm) | Tumor with scar (+/-) | Mean resected specimen size/mm2+SD | Histopathology (adenoma/adenocarcinoma) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Noriya Uedo | NA | Japan | 2007 | 143 | PPIs | 73 | 8 | 68.1 ± 8.5 | 57/16 | NA | 38/43 | NA | 12/69 | 41.0 ± 16.1 | NA |
| H2RAs | 70 | 8 | 65.7 ± 7.6 | 55/15 | NA | 30/48 | NA | 9/69 | 40.5 ± 18.8 | NA | |||||
| Hye-Kyong Jeong | NA | Korea | 2007 | 164 | PPIs | 85 | 8 | 62.9 ± 9.4 | 52/33 | NA | 26/59 | NA | NA | 31.1 ± 9.5 | 71/14 |
| H2RAs | 79 | 8 | 63.5 ± 7.8 | 53/26 | NA | 22/57 | NA | NA | 31.1 ± 10 | 59/20 | |||||
| Tomohiko Richard Ohya | NA | Japan | 2010 | 60 | PPIs | 31 | 4 | 65.4 ± 9.0 | 23/8 | 4/20/10 | NA | 33/1 | NA | NA | NA |
| H2RAs | 29 | 4 | 65.3 ± 8.0 | 21/8 | 1/16/13 | NA | 27/3 | NA | NA | NA | |||||
| Hiroyuki Imaeda | UMIN000001069 | Japan | 2011 | 123 | PPIs | 62 | 8 | 68.4 ± 8.0 | 47/15 | NA | 42/20 | 59/2 | 12/50 | NA | NA |
| H2RAs | 61 | 8 | 67.6 ± 8.5 | 52/9 | NA | 36/25 | 61/0 | 8/53 | NA | NA | |||||
| Toshihiko Tomita | UMIN000001215 | Japan | 2012 | 156 | PPIs | 77 | 8 | 70.4 ± 8.7 | 59/18 | 12/32/33 | NA | 66/11 | 7/70 | 43.8 ± 16.0 | NA |
| H2RAs | 79 | 8 | 70.6 ± 9.5 | 59/20 | 16/33/30 | NA | 71/8 | 9/70 | 40.3 ± 15.6 | NA | |||||
| Jin Seok Jang † | NA | Korea | 2012 | 77 | PPIs+Rebamipide | 40 | 4 | NA | NA | NA | NA | NA | NA | NA | NA |
| H2RAs+Rebamipide | 37 | 4 | NA | NA | NA | NA | NA | NA | NA | NA | |||||
| Myung H. Noh † | NA | Korea | 2013 | 190 | PPIs+Cytoprotective Agents | 92 | 4 | NA | NA | NA | NA | NA | NA | NA | NA |
| H2RAs+Cytoprotective Agents | 98 | 4 | NA | NA | NA | NA | NA | NA | NA | NA | |||||
| T. Kagawa | UMIN000021010 | Japan | 2016 | 225 | PPIs+ Polaprezinc | 150 | 8 | 71.9 ± 9.1 | 91/59 | 20/33/97 | NA | NA | NA | NA | 26/124 |
| P-CAB (Vonoprazan)+ Polaprezinc | 75 | 5 | 72.3 ± 8.4 | 52/23 | 11/12/52 | NA | NA | NA | NA | 10/65 | |||||
| Izumi Tsuchiya | UMIN000017077 | Japan | 2017 | 80 | PPIs | 41 | 8 | 74 | 30/11 | 5/15/19 | NA | 39/2 | NA | NA | 4/37 |
| P-CAB (Vonoprazan) | 39 | 8 | 73 | 27/12 | 9/13/19 | NA | 39/0 | NA | NA | 2/37 | |||||
| Akira Yamasaki | NA | Japan | 2017 | 167 | PPIs | 90 | 4 | 70 (42–90) | 66/24 | 11/44/35 | NA | NA | NA | NA | 6/84 |
| P-CAB (Vonoprazan) | 77 | 4 | 71 (39–87) | 54/23 | 8/29/40 | NA | NA | NA | NA | 2/75 | |||||
| Yohei Horikawa | UMIN 000026391 |
Japan | 2018 | 115 | PPIs | 53 | 2 weeks | 73 (60–86) | 34/19 | 15/20/18 | NA | 46/7 | NA | NA | NA |
| P-CAB (Vonoprazan) | 62 | 2 weeks | 69.5 (47–84) | 44/18 | 12/24/26 | NA | 55/7 | NA | NA | NA | |||||
| Ai Hirai | UMIN000016687 | Japan | 2018 | 149 | PPIs | 75 | 8 | 69.9 ± 11.0 | 55/20 | 4/29/42 | NA | 71/4 | NA | NA | 7/68 |
| P-CAB (Vonoprazan) | 74 | 8 | 73.2 ± 7.5 | 62/8 | 9/27/41 | NA | 60/14 | NA | NA | 8/66 | |||||
| Kenta Hamada | UMIN000017320 | Japan | 2018 | 139 | PPIs | 70 | 8 | 70.1 ± 8.5 | 57/23 | NA | NA | NA | 7/63 | 38 ± 15 | NA |
| P-CAB (Vonoprazan) | 69 | 8 | 70.3 ± 6.8 | 51/18 | NA | NA | NA | 6/63 | 38 ± 14 | NA | |||||
| Yasuaki Ishii | MIN000016835 | Japan | 2018 | 53 | PPIs | 26 | 8 | 70 (66–75.3) | 22/3 | 14/10/2 | NA | NA | NA | 39.8 (26-80) | NA |
| P-CAB (Vonoprazan) | 27 | 8 | 70 (65.3–75) | 23/4 | 12/10/5 | NA | NA | NA | 40.6 (30-54) | NA | |||||
| Hiroyuki Komori | UMIN000017386 | Japan | 2019 | 33 | PPIs | 15 | 4 | 70.9 ± 8.8 | 11/4 | 2/8/5 | NA | NA | NA | NA | NA |
| P-CAB (Vonoprazan) | 18 | 4 | 69 ± 9.3 | 13/5 | 1/4/13 | NA | NA | NA | NA | NA | |||||
| Takashi Ichida | UMIN000019516 | Japan | 2019 | 82 | PPIs+Rebamipide | 39 | 8 | 73.9 (58–88) | 34/5 | 4/18/17 | NA | NA | NA | 38.6 (21-66) | 14/25 |
| P-CAB (Vonoprazan)+Rebamipide | 43 | 8 | 72.4 (52–89) | 31/12 | 7/12/24 | NA | NA | NA | 39.9 (18-66) | 8/35 |
PPIs, proton pump inhibitors; H2RAs, histamine2-receptor antagonists; NA, not available; U/M/L, upper/middle/lower; m/sm, intramucosal cancer/submucosal invasive cancer; SD, standard deviation.
†abstract.